Crossmark

Humanized dual-targeting antibody–drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity

Crossref DOI link: https://doi.org/10.1038/s41401-024-01458-7

Published Online: 2025-01-21

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Minghai https://orcid.org/0000-0003-4402-5018
Ma, Qi

Suthe, Sreedhar Reddy

Hudson, Rachel E.

Pan, Jing-ying

Mikelis, Constantinos

Zhu, Miao-jin

Wu, Zhi-gang

Shi, Dan-rong

Yao, Hang-ping https://orcid.org/0000-0001-6742-7074
License Information

Text and Data Mining valid from 2025-01-21

Version of Record valid from 2025-01-21
More Information

Article History

Received: 13 August 2024

Accepted: 12 December 2024

First Online: 21 January 2025

Competing interests

: The authors declare no competing interests.

: The use of clinical samples was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University (registration numbers: 2017-427-1), with all participants signing informed consent forms. Animal procedures were approved by the same ethics committee (registration numbers: 2017-400-1) and performed in accordance with the Guide for the Care and Use of Laboratory Animals of Zhejiang Province.

Document is current

Any future updates will be listed below